Prevalence of HPV 16/18 for men in each scenario 10, 20 and 50 years after initiation of vaccination (t = 0).

<p>Vaccine coverage was supposed constant in each scenario. In parentheses, % of reduction in HPV prevalence compared to the case without vaccination.</p

Flow diagram in non-vaccinated population.

<p>For one age-group <i>j</i> (j = 1…14) and one group of sexual behavior <i>l</i> (l = 1…4): Black solid arrows represent infection or progression of the disease; black dotted arrows represent clearance of infection or regression of the disease; gray dotted arrows represent exit of the model (due to death or age >84); bold arrows represent specific mortality due to cervical cancer.</p

Expected Diminution of number of deaths (per year) due to cervical cancer after introduction of vaccine compared to number of deaths without vaccine.

<p>Expected Diminution of number of deaths (per year) due to cervical cancer after introduction of vaccine compared to number of deaths without vaccine.</p

Prevalence of HPV 16/18 for women in each scenario 10, 20 and 50 years after initiation of vaccination (t = 0).

<p>Vaccine coverage was supposed constant in each scenario. In parentheses, % of reduction in HPV prevalence compared to the case without vaccination.</p

Incidence of cervical cancer due to HPV 16/18 in French women in each scenario 10, 20 and 50 years after initiation of vaccination (t = 0).

<p>Vaccine coverage was supposed constant in each scenario. In parentheses, % of reduction in cervical cancer incidence compared to the case without vaccination.</p